Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,447 signal articles · 187 in last 24h · 121,672 total before filter · latest 17m ago
187last 24h
1271last 7d
214● bullish (7d)
152● bearish (7d)
205publishers
AllMacro210Earnings441M&A100Regulatory26Product9Analyst13
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
2 Reasons to Like SSB and 1 to Stay Skeptical
StockStory66d agoneutral
2 Reasons to Like SSB and 1 to Stay Skeptical

Since December 2025, SouthState has been in a holding pattern, posting a small return of 1.9% while floating around $98.95. The stock also fell short of the S&P 500’s 8.4% gain during that period.

Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
StockStory66d agoneutral
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?

Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, marking a 37.1% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

3 Reasons FBNC is Risky and 1 Stock to Buy Instead
StockStory66d agobullish
3 Reasons FBNC is Risky and 1 Stock to Buy Instead

Over the past six months, First Bancorp has been a great trade, beating the S&P 500 by 7.2%. Its stock price has climbed to $61.79, representing a healthy 15.6% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

3 Reasons META Has Explosive Upside Potential
StockStory66d agoneutral
3 Reasons META Has Explosive Upside Potential

Over the past six months, Meta’s stock price fell to $569.25. Shareholders have lost 12.1% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This might have investors contemplating their next move.

3 Reasons to Sell LXFR and 1 Stock to Buy Instead
StockStory66d agoneutral
3 Reasons to Sell LXFR and 1 Stock to Buy Instead

Luxfer has had an impressive run over the past six months as its shares have beaten the S&P 500 by 23.2%. The stock now trades at $18.07, marking a 31.6% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

3 Reasons to Sell PRU and 1 Stock to Buy Instead
StockStory66d agoneutral
3 Reasons to Sell PRU and 1 Stock to Buy Instead

Over the past six months, Prudential’s shares (currently trading at $108.28) have posted a disappointing 7.9% loss, well below the S&P 500’s 8.4% gain. This might have investors contemplating their next move.

3 Reasons RLI is Risky and 1 Stock to Buy Instead
StockStory66d agobullish
3 Reasons RLI is Risky and 1 Stock to Buy Instead

Over the past six months, RLI’s stock price fell to $54.37. Shareholders have lost 16.4% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This may have investors wondering how to approach the situation.

Peace Deal Reignites Tech Stock Rally
Barrons.com66d agobullish
Peace Deal Reignites Tech Stock Rally

The Nasdaq had its best day since March after Wall Street used the U.S.-Iran peace deal as just another excuse to pile into technology stocks. The Dow rose 469 points, or 0.9%. Market breadth was actually mediocre, but everything from Big Tech to software and chips were on the rise, along with other risk assets like crypto firms.

3 Reasons to Avoid WRBY and 1 Stock to Buy Instead
StockStory66d agobullish
3 Reasons to Avoid WRBY and 1 Stock to Buy Instead

Warby Parker has been treading water for the past six months, recording a small loss of 1.5% while holding steady at $26.43. The stock also fell short of the S&P 500’s 8.4% gain during that period.